Unknown

Dataset Information

0

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.


ABSTRACT: In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8+ T-cell responses with the goal to elicit tumor regression and avoid toxicities associated with nonspecific immunotherapies. In this review, we provide an overview of the central role of T-cell immunity in the treatment of advanced RCC. Clinical outcomes for antigen-targeted vaccines or other T-cell-engaging therapies for RCC are summarized and evaluated, and emerging new strategies to enhance the effectiveness of antigen-specific therapy for RCC are discussed.

SUBMITTER: Xu Y 

PROVIDER: S-EPMC8189101 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6463563 | biostudies-literature
| S-EPMC5215367 | biostudies-literature
| S-EPMC3332131 | biostudies-literature
| S-EPMC10777977 | biostudies-literature
| S-EPMC10968958 | biostudies-literature
| S-EPMC8115394 | biostudies-literature
| S-EPMC6976508 | biostudies-literature
| S-EPMC5723125 | biostudies-literature
| S-EPMC10114990 | biostudies-literature
| S-EPMC6307608 | biostudies-literature